Department of Obstetrics and Gynecology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
J Matern Fetal Neonatal Med. 2021 Feb;34(3):366-372. doi: 10.1080/14767058.2019.1608177. Epub 2019 Apr 24.
Growth-restricted fetuses have been excluded from many randomized trials of prostaglandins for labor induction. As prostaglandins, particularly misoprostol, are associated with increased rates of cesarean delivery for nonreassuring fetal heart tracing, it is important to assess their safety in pregnancies at higher risk of this complication. The objective of this study was to estimate the association between use of prostaglandins for labor induction in term singleton pregnancies complicated by delivery of small-for-gestational age (SGA) neonates and the risk of cesarean delivery for nonreassuring fetal status (NRFS). Retrospective cohort study of singleton deliveries ≥37 weeks following induction of labor in patients with SGA (birthweight <10% percentile for gestational age). Patients with prior cesarean delivery or neonates with major congenital anomalies were excluded. Patients were categorized by exposure to prostaglandins. The primary outcome was cesarean delivery for NRFS. Secondary outcomes were any cesarean delivery, a composite of a 5-min Apgar score <7, admission to the neonatal intensive care unit, or neonatal death, and a composite of maternal morbidity (transfusion, postpartum hemorrhage, wound infection, endometritis, fever). Propensity scores for exposure were estimated using a logistic regression model, including parity, comorbidities, and Bishop score. Stabilized weights from inverse probability of treatment weighting were used. Outcomes were compared with relative risks (RRs) and 95% confidence intervals (CIs). There were 1097 patients: 587 (53.5%) exposed to prostaglandins and 510 (46.5%) unexposed. Covariates were balanced in the stabilized sample. Overall, 166 (15.1%) patients had cesarean deliveries for NRFS. In unadjusted analysis, prostaglandin use was associated with an increased RR of cesarean for NRFS (18.3 versus 11.0%, RR: 1.71, 95% CI: 1.27-2.30). In propensity-score-weighted analysis, the RR for cesarean for NRFS was 1.22 (95% CI: 0.93-1.59). There was no significant association between prostaglandin exposure and all-cause cesarean delivery, maternal morbidity, or neonatal morbidity. In propensity score analysis, there was no association between the use of prostaglandins for labor induction at term and cesarean for NRFS in pregnancies complicated by SGA. However, given the retrospective nature of the study, these results should be interpreted with caution.
生长受限的胎儿已被排除在许多前列腺素用于引产的随机试验之外。由于前列腺素,特别是米索前列醇,与非胎儿心追踪令人安心的情况下剖宫产率增加有关,因此评估它们在有这种并发症风险的妊娠中的安全性很重要。本研究的目的是估计在因胎儿生长受限而分娩的足月单胎妊娠中使用前列腺素诱导分娩与非胎儿状态令人安心的剖宫产率(NRFS)之间的关联。这是一项回顾性队列研究,纳入了因胎儿生长受限(出生体重<妊娠龄第 10 百分位)而接受诱导分娩的单胎妊娠患者。排除了既往剖宫产或新生儿有重大先天畸形的患者。根据是否接触前列腺素对患者进行分类。主要结局为 NRFS 的剖宫产。次要结局为任何剖宫产、5 分钟 Apgar 评分<7、新生儿重症监护病房入院或新生儿死亡、产妇发病率(输血、产后出血、伤口感染、子宫内膜炎、发热)的复合结局。使用逻辑回归模型估计暴露的倾向评分,包括产次、合并症和 Bishop 评分。使用逆概率治疗加权法的稳定权重。用相对风险(RR)和 95%置信区间(CI)比较结局。共纳入 1097 例患者:587 例(53.5%)接触前列腺素,510 例(46.5%)未接触前列腺素。稳定样本中协变量平衡。总体而言,166 例(15.1%)患者因 NRFS 行剖宫产。在未调整分析中,前列腺素的使用与 NRFS 的剖宫产 RR 增加相关(18.3%比 11.0%,RR:1.71,95%CI:1.27-2.30)。在倾向评分加权分析中,NRFS 的剖宫产 RR 为 1.22(95%CI:0.93-1.59)。前列腺素暴露与全因剖宫产、产妇发病率或新生儿发病率之间无显著关联。在倾向评分分析中,在因胎儿生长受限而分娩的足月妊娠中使用前列腺素诱导分娩与 NRFS 无关。然而,鉴于研究的回顾性性质,应谨慎解释这些结果。